Retatrutide Weight Loss Slimming Product Peptide 10mg 20mg 30mg Vials Reta
35 Inquiries
129954-34-3
Pharmaceutical Grade
99.999%
CHIAN
china
10vials/box
2027-08-26
Retatrutide,Tirzepatide,Semaglutide,GHK-CU
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionSELANK Synthetic is a single, non-glycosylated polypeptide chain containing 7 amino acids, having a molecular mass of 751.89 Dalton and a Molecular formula of C33H57N11O9.Basic Info
-
Product Name:
Selank peptide
Other Name:Selank peptide;SelankAcetate;PL14736;L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-proline;L-THREONYL-L-LYSYL-L-PROLYL-L-ARGINYL-L-PROLYLGLYCYL-L-PROLINE; MONOACETATE;H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH;SLANK;Selank peptid
CAS No.:129954-34-3
Molecular Formula:C33H57N11O9
InChIKeys:JTDTXGMXNXBGBZ-YVHUGQOKSA-N
Molecular Weight:751.87
Exact Mass:751.43407244
EC Number:232-660-2
UNII:TS9JR8EP1G
Categories:
Characteristics-
Density:
1.53±0.1 g/cm3(Predicted)
Melting Point:134-136 °C
PKA:3.43±0.20(Predicted)
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Retatrutide,Tirzepatide,Semaglutide,GHK-CU
-
Location:
Room 1209, 12th Floor, Unit 1, Building 1, Block A, Shenglong Plaza, No.80 Weiyang Road, Weiyang District, Xi'an City, Shaanxi Province, P.R.China
-
Payment Terms:
TT against copy of documents,D/A,100% TT in advance
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2025
-
-
Inquiry History35 Inquiries
Country Product Purchase Quantity Date Posted
United States
Selank 99% Purity 129954-34-3
1 G Jan 23, 2026
Greece
selank
10 MG May 20, 2026
United States
N acetyl selank
500 MG Apr 30, 2026
United States
Selank
100 MG Apr 24, 2026
Italy
Nacetyl selank
1 MT Apr 22, 2026
Oman
Selank
1 G Mar 4, 2026
United States
Selank
30 40' Fcl Oct 14, 2025
United States
selank
30 MG May 25, 2026
Brazil
Selank
10 MT Apr 7, 2026
United States
selank
1 G Mar 13, 2026
United States
Selank
1 G Mar 9, 2026
United Kingdom
Selank
1 G Dec 22, 2025
United States
Selank
20 MG Nov 10, 2025
United States
NA-Selank Amidate
10 MG Sep 18, 2025
United Kingdom
Selank
100 MG Jul 15, 2025
United States
N-Acetyl Selank Amidate
1 KG Jan 9, 2025
United States
Selank
10 Mar 29, 2024
Poland
Selank
10 G Feb 18, 2024
United States
Selank
1 G Jan 27, 2024
United States
selank
100 MG Jul 7, 2026 Post an enquiry for this product
t...